口服扁平苔藓局部外用他克莫司的结局与长期治疗方案
该研究回顾性分析了2015至2020年间连续诊断为口腔扁平苔藓并接受0.03%他克莫司口服液局部治疗的57例患者(74%为女性,中位年龄66岁),其中56例(98%)曾接受局部糖皮质激素治疗。治疗后3、6、12、24个月客观缓解(完全或显著缓解)率分别为28%、62%、87%、97%,主观缓解率分别为16%、48%、69%、83%。结论认为局部他克莫司可作为对强效局部糖皮质激素难治的口腔扁平苔藓的有效二线治疗,治疗频率在维持期常可下调,需定期随访以识别可能的鳞状细胞癌。
要点
- 57例口腔扁平苔藓患者中98%曾用局部糖皮质激素,局部他克莫司治疗后24个月客观缓解达97%。
- 治疗频率可从初始每日两次逐渐减至每日一次或更少,24个月时87%患者可减量。
- 41%患者曾完全停药,其中67%在中位3.3个月后复发;4例(7%)观察期间发生鳞状细胞癌。
核心结论
- 局部他克莫司可成为对强效局部糖皮质激素难治的口腔扁平苔藓的有效二线治疗。
- 维持期治疗频率常可下调,治疗应同时参考临床活动性体征与主观不适。
- 需要定期随访以识别可能的鳞状细胞癌。
研究设计与样本
- 回顾性分析2015年至2020年间在临床环境中连续诊断并接受局部他克莫司(0.03%口服液)治疗的口腔扁平苔藓患者。
- 共纳入57例患者,74%为女性,中位年龄66岁;56例(98%)既往接受过局部糖皮质激素治疗。
- 客观临床反应采用4级量表(完全缓解、显著缓解、部分缓解和无反应),主观受损采用3级量表(重度、中度和无)。
主要发现
- 治疗后3、6、12、24个月达到客观缓解(显著或完全缓解)的患者比例分别为28%、62%、87%和97%。
- 治疗后3、6、12、24个月报告主观缓解的患者比例分别为16%、48%、69%和83%。
- 治疗频率从初始每日两次逐渐减至每日一次或更少的患者比例在3、6、12、24个月分别为28%、61%、78%和87%。
- 41%的患者曾完全停止治疗,其中67%在中位3.3个月后出现复发。
- 观察期间4例患者(7%)发生鳞状细胞癌,除此之外仅有少数轻微副作用。
关键数值与推荐
- 客观缓解定义为4级量表上的显著缓解或完全缓解。
- 主观受损采用3级量表评估:重度、中度和无。
- 治疗频率可从初始每日两次逐渐减至每日一次或更少。
临床怎么用
- 作者认为局部他克莫司可作为对强效局部糖皮质激素难治的口腔扁平苔藓的有效二线治疗。
- 作者指出维持期治疗频率常可下调,治疗决策应同时参考临床活动性体征与主观不适。
- 作者强调需要定期随访以识别可能的鳞状细胞癌。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Topical tacrolimus has been shown to be beneficial in the treatment of oral lichen planus (OLP). However, long-term effects and its optimal application protocol with gradual reduction have not been studied. Accordingly, we analysed the clinical response of OLP to tacrolimus in our daily clinical practice with a focus on the optimal long-term therapeutic scheme. METHODS: Retrospective analysis of all consecutive patients diagnosed with OLP and treated with topical tacrolimus (0.03% oral rinse) in a clinical setting between 2015 and 2020. The objective clinical response was measured by a 4-point scale (complete remission, major remission, partial remission and no response), and subjective impairment by a 3-point scale (severe, moderate and none). RESULTS: Fifty-seven patients (74% women; median age: 66 years) were included. Fifty-six (98%) patients had prior treatment with topical steroids. After introduction of tacrolimus, objective remission (major or complete) was reached by 28%, 62%, 87% and 97% of patients after 3, 6, 12 and 24 months respectively. Subjective remission was reported by 16%, 48%, 69% and 83% after 3, 6, 12 and 24 months of treatment respectively. The treatment frequency could be gradually reduced from initially twice daily to once daily or less in 28%, 61%, 78% and 87% after 3, 6, 12 and 24 months respectively; 41% of patients completely suspended the treatment at one point, but 67% of them experienced a relapse after a median time of 3.3 months. Four patients (7%) developed a squamous cell carcinoma (SCC) during the observation period. Otherwise, there were only few and minor side-effects. CONCLUSION: Topical tacrolimus can be an effective second-line therapy for OLP refractory to potent topical corticosteroids. The therapy frequency can often be reduced during the maintenance period. Both signs of clinical activity and subjective impairment should guide therapy. Regular follow-up is necessary to recognize possible SCC.
引用
- Utz S, Suter VGA, Cazzaniga S, et al. Outcome and long-term treatment protocol for topical tacrolimus in oral lichen planus. J Eur Acad Dermatol Venereol. 2022. PMID: 35870137. doi:10.1111/jdv.18457
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。